Assura Plc (LON:AGR – Get Free Report) insider Jayne Cottam purchased 306 shares of the business’s stock in a transaction on Tuesday, May 6th. The shares were purchased at an average cost of GBX 49 ($0.65) per share, for a total transaction of £149.94 ($199.47).
Jayne Cottam also recently made the following trade(s):
- On Monday, April 7th, Jayne Cottam bought 348 shares of Assura stock. The shares were acquired at an average price of GBX 43 ($0.57) per share, for a total transaction of £149.64 ($199.07).
- On Wednesday, March 5th, Jayne Cottam bought 363 shares of Assura stock. The stock was acquired at an average price of GBX 41 ($0.55) per share, with a total value of £148.83 ($197.99).
Assura Stock Performance
Shares of AGR stock opened at GBX 48.72 ($0.65) on Friday. The firm has a 50 day moving average of GBX 46.94 and a 200-day moving average of GBX 41.66. The company has a market cap of £1.59 billion, a price-to-earnings ratio of -46.57, a price-to-earnings-growth ratio of 3.60 and a beta of 0.37. The company has a quick ratio of 2.84, a current ratio of 0.89 and a debt-to-equity ratio of 85.05. Assura Plc has a 52 week low of GBX 35.24 ($0.47) and a 52 week high of GBX 49.20 ($0.65).
Assura Company Profile
Assura plc is a specialist healthcare property investor and developer. We enable better health outcomes through our portfolio of more than 600 healthcare buildings across the UK and Ireland, from which over six million patients are served.
We BUILD for health, having developed over 100 new healthcare buildings in our history, and at the heart of our strategy sits The Bigger Picture; Healthy Environment (E), Healthy Communities (S), Healthy Business (G).
Assura plc achieved B Corp certification in July 2024 – the first FTSE 250 business to do so.
Further Reading
- Five stocks we like better than Assura
- Health Care Stocks Explained: Why You Might Want to Invest
- Google Is Betting Big on Nuclear Reactors—Should You?
- Want to Profit on the Downtrend? Downtrends, Explained.
- Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs
- Find and Profitably Trade Stocks at 52-Week Lows
- Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings
Receive News & Ratings for Assura Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assura and related companies with MarketBeat.com's FREE daily email newsletter.